retatrutide mash just delivered the first top-line Phase 3 results for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇 Retatrutide vs. Ozempic: The Triple

Conclusion We report the development of antioxidant-loaded, gel-forming eye drops for the treatment of RP with once-daily application

doi: 10.1371/journal.pone.0104873

Restraint Supply shortages and compounding restrictions Australia is facing widespread shortages of GLP-1 receptor agonists such as semaglutide (Ozempic) and dulaglutide (Trulicity), since late 2022 and has been a major issue which is due to growing demand surpassing production, further affecting type 2 diabetes care, cardiovascular risk reduction and weight management in patients

This combination of effects leads to reduced calorie intake, which is the primary mechanism behind the significant weight loss observed in clinical trials

Peptide Reconstitution & Concentration Calculator Accurate research peptide concentration, reconstitution and dilution calculations for lyophilised peptides